Search

Sponsor prospectus

Dear Partner,

Welcome to the digital EHA Sponsor Prospectus 2024-2025. Over the past two years, the world of congresses, meetings, and education has drastically changed.

Read more

What an EHA Kick-off Grant supports

Our EHA Kick-off Grant supports basic and translational lab-based research in hematology. Costs that can be supported by an EHA Kick-off Grant
Lab consumables. Max € 5,000 for equipment, if properly justified.

Read more

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Read more

Publications

Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Atallah E, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D.

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more

Policy & advocacy

At the core of EHA’s advocacy efforts are four priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.

Read more

Pieter Sonneveld appointed Officer in the Order of Orange-Nassau

The EHA Board congratulates former EHA President Professor Pieter Sonneveld on his appointment as an Officer of the Order of Orange-Nassau by His Majesty King Willem-Alexander of the Netherlands.

Read more

EHA leads Tutorial in Kazakhstan for better understanding of lymphomas

EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more